Development and initial validation of the Bristol Impact of Hypermobility questionnaire by Palmer, S. et al.
                          Palmer, S., Cramp, A. F. L., Lewis, R., Gould, V. C., & Clark, E. M. (2016).
Development and initial validation of the Bristol Impact of Hypermobility
questionnaire. Physiotherapy. DOI: 10.1016/j.physio.2016.04.002
Peer reviewed version
Link to published version (if available):
10.1016/j.physio.2016.04.002
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at http://www.sciencedirect.com/science/article/pii/S0031940616300177. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
1 
 
TITLE PAGE 
 
Title: Development and initial validation of the Bristol Impact of Hypermobility (BIoH) 
questionnaire  
 
Authors: Palmer Sa, Cramp Fa, Lewis Rb, Gould Gc, Clark EMc 
 
Author affiliations: aDepartment of Allied Health Professions, University of the West 
of England, Bristol, UK. Shea.Palmer@uwe.ac.uk, Fiona.Cramp@uwe.ac.uk  
bDepartment of Physiotherapy, North Bristol NHS Trust, Bristol, UK. 
Rachel.Lewis@nbt.nhs.uk  
cMusculoskeletal Research Unit, University of Bristol, Bristol, UK. 
Gin.Gould@googlemail.com, Emma.Clark@bristol.ac.uk  
 
Corresponding author: Professor Shea Palmer, Department of Allied Health 
Professions, University of the West of England, Blackberry Hill, Bristol, BS16 1DD, 
UK. Tel. +44 117 3288919, Shea.Palmer@uwe.ac.uk  
 
Word count: 3 303 
 
 
 
  
2 
 
ABSTRACT 
 
Objectives: Stage 1: Identify the impact of Joint Hypermobility Syndrome (JHS) on 
adults; Stage 2: Develop a questionnaire to assess the impact of JHS; Stage 3: 
Undertake item reduction and establish the questionnaire’s concurrent validity. 
Design: A mixed methods study, employing qualitative focus groups and interviews 
(Stage 1); a working group of patients, clinicians and researchers, and ‘think aloud’ 
interviews (Stage 2); and quantitative analysis of questionnaire responses (Stage 3). 
Setting: Stages 1 and 2 took place in one secondary care hospital in the United 
Kingdom (UK). Stage 3 recruited members of a UK-wide patient organisation. 
Participants: A total of n=15, n=4, and n=615 participants took part in Stages 1, 2 
and 3 respectively. Inclusion criteria were: ≥18 years; a diagnosis of JHS; no other 
conditions affecting physical function; able to give informed consent; and able to 
understand and communicate in English.  
Interventions: None. 
Main outcome measures: The development of a questionnaire to assess the 
impact of JHS.  
Results: Stage 1: A wide range of impairments, activity limitations and participation 
restrictions were identified. Stage 2: A draft questionnaire was developed and refined 
following ‘think aloud’ analysis, leaving 94 scored items. Stage 3: Items were 
removed on the basis of low severity and/or high correlation with other items. The 
final ‘Bristol Impact of Hypermobility’ (BIoH) questionnaire has 55 scored items and 
correlated well with the Physical Component Score of the Short Form 36 health 
questionnaire (r=-0.725). 
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Conclusions: The BIoH questionnaire demonstrated good concurrent validity. 
Further psychometric properties need to be established.  
 
Key words: Hypermobility, joint; Joint laxity, familial; Questionnaires; Interview; 
Focus Groups; Validity of results. 
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MANUSCRIPT 
 
TITLE 
Development and initial validation of the Bristol Impact of Hypermobility (BIoH) 
questionnaire  
 
 
INTRODUCTION 
Joint Hypermobility Syndrome (JHS) is a heritable connective tissue disorder 
characterised by excessive joint range of motion and pain [1]. It has been reported to 
affect up to 5% of women and 0.6% of men [2], although there is a lack of good-
quality epidemiological evidence for the true prevalence of JHS in the general 
population. The prevalence in musculoskeletal practice contexts is likely to be very 
high, however, with 30% of those referred to a Musculoskeletal Triage Clinic in the 
United Kingdom (UK) meeting the Brighton diagnostic criteria [3,4]. 
 
JHS is associated with a wide range of problems including pain, fatigue, 
proprioception deficits and repeated cycles of injury, anxiety and catastrophizing [5]. 
It may also be associated with a range of autonomic and gastrointestinal symptoms, 
and functional difficulties indicative of developmental coordination disorder/dyspraxia 
[6]. Empirical data has shown that, when compared with healthy controls, JHS has a 
significant impact on outcomes such as exercise endurance, gait, pain, 
proprioception, strength, function and quality of life both in children [7,8,9,10] and 
adults [11,12,13,14]. A recent systematic review and meta-analysis confirmed the 
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impact of JHS on a range of psychological variables such as fear, agoraphobia, 
anxiety, depression and panic disorders [15]. 
 
Physiotherapy, particularly exercise, is a mainstay of treatment for JHS, although 
recent systematic reviews highlighted the lack of research evidence [16,17]. The 
trials in adults included in those reviews used a range of patient reported outcome 
measures (PROMs), including the Short-Form 36 (SF-36) [18], the Arthritis Impact 
Measurement Scales 2 (AIMS-2) [13] and a questionnaire developed by Barton and 
Bird [19]. Of those, only the SF-36 captured improvements following exercise [18]. 
Only one of the five AIMS-2 subscales changed with exercise [13] and there were no 
changes evident in Barton and Bird’s questionnaire [19]. So, if exercise is effective 
(which has yet to be convincingly demonstrated [16]), only the SF-36 seemed to 
demonstrate sufficient measurement sensitivity. Closer inspections of these PROMs 
identify a lack of face, content and construct validity [20] for many issues reported by 
people with JHS [5]. For example Barton and Bird’s questionnaire [19] focused on 
lower limb activity (such as going up and down stairs, squatting, standing up and 
walking), failing to reflect upper limb functional difficulties. Neither the process of 
development nor the psychometric properties of the questionnaire were reported. A 
recent survey of physiotherapy practice in the UK [21] highlighted a lack of 
congruence between the aims of physiotherapy management for JHS and the tools 
used to assess the effectiveness of management. There is therefore a need to 
develop a condition-specific, psychometrically sound, outcome measure to underpin 
future research and clinical practice in this area. 
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This project had a number of related aims. Stage 1: To identify the impact of JHS on 
adults with the condition to inform initial patient-specific questionnaire items; Stage 2: 
To develop a questionnaire to assess the personal impact of JHS; Stage 3: To 
reduce the number of questionnaire items and establish the concurrent validity of the 
new questionnaire against the SF-36. 
 
 
METHOD 
Ethical approval was obtained from the South West 5 NHS Research Ethics 
Committee (10/H0107/46). The research was conducted in three stages as follows.  
 Stage 1 – Identification of questionnaire items. Methods: focus groups and 
telephone interviews with people with JHS. 
 Stage 2 – Development of the initial questionnaire. Methods: working group of 
patient research partners and researchers; ‘think aloud’ evaluation. 
 Stage 3 – Item reduction and validation of the questionnaire. Methods: 
administration of the initial questionnaire and SF-36 to members of the 
Hypermobility Syndromes Association (HMSA), a UK-based patient organisation; 
item removal; assessment of the concurrent validity of the final questionnaire 
items against the SF-36; production of the final questionnaire. 
 
Participants 
Inclusion criteria (Stages 1-3): Diagnosed with JHS; ≥18 years old; no other formally 
diagnosed conditions affecting physical function (such as inflammatory arthritis, 
osteoarthritis or neurological conditions); able to give informed consent; able to 
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understand and communicate in English. Stage 2 also recruited all five members of 
the research team.  
 
The sources of recruitment at each stage were as follows. 
Stages 1-2: Patients who met the Brighton criteria [3] for JHS (confirmed by a 
physiotherapist) who had been seen by the physiotherapy service at North Bristol 
NHS Trust in the previous two years were sent an invitation letter, participant 
information sheet and a reply slip. All participants completed informed signed 
consent. Two patient research partners (people with JHS who advised on the design 
and conduct of all aspects of the research, including the wording of patient 
information sheets and consent forms, and sat as equal members of a study steering 
group), and one further person with JHS who contributed to the working group during 
Stage 2 were recruited from the same cohort. 
Stage 3: Adult members of the HMSA were sent an invitation letter, participant 
information sheet and a copy of the questionnaires. Diagnosis of JHS was self-
declared. Completion and return of the questionnaires was taken as implied consent. 
 
Procedure 
Stage 1  
Two focus groups with people with JHS were conducted to explore the impact of the 
condition. An option to undertake a telephone interview was provided for those who 
were unable or unwilling to attend a focus group. A loose topic guide was used to 
steer the focus group and interview discussions. The same researcher (GG) 
conducted all focus groups and interviews, with another researcher (SP) taking notes 
during the focus groups to aid transcription. Focus groups and interviews were 
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audio-recorded, transcribed verbatim and anonymised. Open coding of the 
transcripts was used to identify individual questionnaire items, and codes were 
discussed in detail and verified by two researchers (GG and SP). Thematic analysis 
of the data did not progress beyond this first level of coding as the aim was limited to 
identification of individual items.  
 
Stage 2 
A working group was convened to develop the initial questionnaire. The group 
comprised three people with JHS (including two patient research partners) and five 
researchers. The researchers included clinical and academic expertise in 
physiotherapy and medical rheumatology and expertise in outcome measure 
development. Meetings were supplemented by e-mail and telephone 
correspondence and two researchers (GG and SP) took the lead in developing and 
revising draft questionnaires between meetings based on working group feedback 
and discussion. The working group initially discussed in detail the items developed 
from Stage 1 and agreed the specific wording of individual questions and response 
options, and the overall design of a first draft questionnaire. The three Bristol 
Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF-NRS) [22,23] were 
included with permission. The BRAF-NRS assess intensity of, effect of and coping 
with fatigue and, although developed for Rheumatoid Arthritis, have generic wording. 
This first draft questionnaire was then subjected to ‘think aloud’ analysis (also known 
as cognitive interviewing [24]) where people with JHS were asked to verbalise their 
thoughts whilst completing the questionnaire. This method was used to explore 
patients’ understanding of the questions and their responses to them. Interviews 
were audio-recorded, transcribed and anonymised. The transcriptions were analysed 
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question by question to identify any salient points and a report was produced for the 
working group. Further refinements were then made and the initial JHS 
questionnaire agreed with the working group. 
 
Stage 3 
An invitation letter, participant information sheet, a copy of the questionnaires (the 
initial JHS questionnaire, SF-36 and a demographics questionnaire) and a pre-paid 
return envelope were distributed by mail to all 1 502 adult members of the HMSA 
(identified by the membership secretary). No reminders were sent. Completed 
questionnaires were systematically entered into an IBM SPSS Statistics spreadsheet 
by a research associate employed on the project. Data accuracy was audited and 
verified by the lead author (SP). SF-36 scoring software v4.5 (Optum Insight) was 
used to calculate SF-36 component and subscale scores. Descriptive statistics and 
Kolmogorov-Smirnov tests for normality of data distributions were calculated for all 
items. A correlation matrix using Spearman’s Rank Correlation coefficients was 
produced to investigate the relationships between all scored items on the JHS 
questionnaire. Two criteria were then employed to inform decisions on whether to 
remove or retain individual items (although the BRAF-NRS were retained unaltered).  
1. Median score ≤40% severity. This criterion helped to identify items that were 
considered relatively less important. 
2. Strong correlations (r≥0.7) between individual items. This criterion helped to 
identify items that were potentially redundant (i.e. multiple items may have been 
measuring similar things). The wording of strongly correlated items were looked 
at closely and an iterative process was used to inform which questions should be 
retained and which should be removed.  
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The scores for the final JHS questionnaire items were then added to give a total 
score and this was correlated against the component and subscale scores of the SF-
36 to test concurrent validity. 
 
Given the pragmatic design of the questionnaire, including incorporation of the 
BRAF-NRS and the range of different response categories employed, it was 
considered inappropriate to try to identify separate domains within the JHS 
questionnaire using exploratory factor analysis.  
 
 
RESULTS 
Stage 1 
Stage 1 recruited 15 people with JHS and they contributed to two focus groups (both 
n=6/15) and telephone interviews (n=3/15). 13/15 (86.7%) were women. 2/15 
(13.3%) were aged 18-25 years, 7/15 (46.7%) 26-35 years, and 6/15 (40.0%) 36-45 
years. A wide range of issues related to the impact of JHS were raised, 
encompassing impairment, activity limitations and participation restrictions [25]. The 
issues identified included items common to many other long term musculoskeletal 
conditions, such as pain and fatigue and difficulties with standing, walking and 
negotiating stairs. However there were other more specific issues identified such as 
balance and coordination problems, unexpected pain, joints giving way and 
weakness. It was also clear that participants commented on both the intensity and 
frequency of issues. 
 
Stage 2 
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The working group devised a draft questionnaire relatively easily, using a mixture of 
numerical rating scales (similar to the BRAF-NRS) and Likert scales. It was decided 
that questions with common response options should be grouped together to 
facilitate navigation and completion and that larger scores should equate to greater 
impact. Four participants (all women, aged 19-40 years) took part in the think aloud 
analysis and the draft questionnaire was generally very well received, with the 
questions and response options generally clear. Participants stated that there was 
some repetition, with similar questions asked in slightly different ways, but the 
working group decided to keep all questions as part of Stage 3 was designed to 
identify closely correlated questions. The findings of the think aloud analysis 
informed a few minor changes to wording but was otherwise useful in confirming the 
face validity of the draft questionnaire. The individual questionnaire items and 
response options are evident from the final ‘Bristol Impact of Hypermobility’ (BIoH) 
questionnaire (supplemental material) and from Table 3 (those items that were later 
excluded). The resultant draft questionnaire contained 94 scored items (and a further 
10 identifying area of pain). 
 
Stage 3 
A total of 636/1 502 responses were received (42.3% response rate), of which 21 
were excluded (reasons for exclusion: 12 aged <18 years; 9 omitted at least one 
section of the JHS questionnaire meaning that a total score could not be calculated). 
The remaining 615 were included in analysis. 
 
Kolmogorov-Smirnov tests revealed that the data for age, individual JHS 
questionnaire items and the majority of SF-36 subscales deviated from normality (all 
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p<0.001). The only exception was the SF-36 Physical Component Score (p=0.200).  
Non-parametric analyses were therefore employed throughout.  
 
The median (IQR) age of participants was 39 (17) years. 81/599 (13.5%) were aged 
18-25 years, 156/599 (26.0%) 26-35 years, 186/599 (31.1%) 36-45 years, 100/599 
(16.7%) 46-55 years, 56/599 (9.3%) 56-65 years, 18/599 (3.0%) 66-75 years, and 
2/599 (0.3%) 76-85 years. Other participant characteristics are presented in Table 1. 
The majority were women (582/614, 94.8%) of white ethnicity (602/614, 98.0%). 
Participants were generally well educated (292/519, 56.3% had a university degree 
or equivalent) and a slight majority were in paid employment (339/600, 56.5%). 
 
Insert Table 1 here. 
 
Participants complained of pain in a wide range of painful areas (Table 2). Figure 1 
illustrates the total number of painful areas reported by participants. The median 
(IQR, range) number of painful areas was 8.0 (3.0, 0-10). 
 
Insert Table 2 here. 
 
Insert Figure 1 here. 
 
A total of 39 questions were removed on the basis of a median score ≤40% and/or a 
strong correlation with other questions (r≥0.7) (supplemental information 1).  
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The remaining 55 questionnaire items comprised the final ‘Bristol Impact of 
Hypermobility’ (BIoH) questionnaire and gave a single composite score of 360, with 
higher scores representing more severe impact (please see supplemental 
information 2 and 3). It takes approximately 10 minutes to complete. The median 
(IQR, range) BIoH score was 234 (81, 55-355). The total BIoH scores were 
correlated against the SF-36 scores to investigate concurrent validity and the results 
are presented in Table 3. 
 
Insert Table 3 here. 
 
The BIoH questionnaire correlated most closely with the Physical Component Score 
(PCS) (r=-0.725), reflecting less the Mental Component Score (MCS) (r=-0.447). 
This was also reflected in the subscales, with high correlation coefficients (r≥-0.7) for 
physical function, role physical and bodily pain. The only MCS subscale that had a 
strong correlation with the BIoH questionnaire values was social functioning. 88% 
(541/615) and 52% (320/615) of the cohort were below general population norms for 
the SF36 PCS and MCS respectively. There was no correlation between age and 
total BIoH score (Spearman’s Rank Correlation Coefficient r=-0.070, p=0.085). 
 
The median (IQR) BRAF-NRS scores for severity, effect and coping were 7.0 (2.0), 
7.0 (4.0) and 4.0 (4.0) respectively, indicating that people with JHS experience a 
high level of fatigue, it has a strong effect on their lives, but that they cope with 
fatigue relatively well. The mean (SD) values were 6.8 (2.1), 6.6 (2.6) and 4.1 (2.4) 
respectively. 
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DISCUSSION 
The new BIoH questionnaire is the first condition-specific tool validated for JHS. It 
was developed in close collaboration with people with JHS and seems 
comprehensive in reflecting items of importance. Scores correlate strongly with the 
PCS of the SF-36, with the strongest relationship being evident with Bodily Pain (BP) 
domain scores. Correlation with the MCS of the SF-36 was much more modest. This 
suggests that the BIoH questionnaire predominantly captures information about 
physical function rather than psychological function. Given the predominance of 
physical function items identified by focus group and interview participants, this 
seems an appropriate finding. It may be that further one-to-one interviews may have 
elicited further participation-level outcomes of importance to individuals, as such 
issues may be more difficult to discuss in a focus group context.  
 
There was a very high prevalence of pain in a wide range of body areas, many of 
which are not reflected in the current Brighton diagnostic criteria [3], such as the 
shoulders and neck. It should be noted that the wording of the BIoH questionnaire 
does not distinguish between unilateral and bilateral pain and therefore the actual 
number of areas is likely to be higher than reported here. However there was a clear 
trend towards participants reporting a high number of affected body areas, with the 
highest reported prevalence being of pain in all ten areas. Self-reported tender joint 
counts are used in other conditions such as rheumatoid arthritis (RA) and have been 
found to correlate well with clinician assessment [26]. It is difficult to directly compare 
data due to differing methodologies but Scott and Scott [27] reported that only 25% 
of consecutive people with RA (n=307) reported 6 or more tender joints out of 28 
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joints assessed. This threshold equates to just over 20% of the joints assessed. By 
way of comparison, 99.2% (609/614) respondents in the current study reported pain 
in 20% (two or more) of the 10 body areas assessed. In fibromyalgia the mean 
‘tender point’ count has been reported as 14.7 out of 18 [28], although these no 
longer form part of the diagnostic criteria and they include a mixture of joint and 
muscle points. Nevertheless the prevalence is akin to that identified for JHS in the 
present study. Clark et al [6] identified that 19% of people with JHS reported a 
concomitant diagnosis of fibromyalgia and therefore some overlap is to be expected. 
What is clear is that pain in multiple body areas seems to be a very significant issue 
in the JHS population described here. 
 
Terry et al [5] identified fatigue as one of the major factors associated with JHS. The 
BIoH questionnaire therefore included the three BRAF-NRS questions which assess 
fatigue severity, effect and coping. In RA the mean (SD) BRAF-NRS scores have 
been reported as follows (n=229): severity 6.8 (1.8), effect 6.5 (2.2), and coping 5.7 
(2.3) [22]. The present study has found that people with JHS seem to experience 
fatigue levels that are very similar to people with RA, certainly in terms of severity 
and effect. Interestingly, the coping with fatigue question is reverse scored, with 
patients choosing a lower score to represent worse coping. Many respondents in the 
present study seem to have scored this question inappropriately, choosing a high 
score when they had also chosen a high score for severity and effect (and vice-
versa). Our addition of a note on how to score this item may have caused some 
confusion for respondents. For the purpose of analysis the scores for this item were 
calculated as described by the developers [22] but there is a question mark over the 
16 
 
appropriateness of some responses. The very small contribution of this one item to 
the overall BIoH score is unlikely to have affected the findings. 
 
Although the results of the initial validation of the BIoH questionnaire are promising, 
it should be noted that other psychometric properties such as test-retest reliability, 
sensitivity to change and the minimum clinically important difference have yet to be 
established. Given its condition-specific focus, it is anticipated that the BIoH 
questionnaire will be sensitive to changes in physical function which is a key aim of 
physiotherapy management [21]. However this requires future verification.  
 
Limitations and strengths 
The response rate in Stage 3 (636/1 502, 42.3%) might have been improved through 
strategies such as sending reminders or providing an online response option. 
Respondents to Stage 3 included a slightly older age range than those who 
contributed to the Stage 1 development of the questionnaire items, although 71% 
were in the same 18-45 year age range (423/599) and no relationship was observed 
between age and total BIoH score. The proportion of women was largely similar 
between Stage 1 and Stage 3. Validation has therefore been conducted on a 
generally similar group to that which generated the questionnaire items. Members of 
the HMSA who responded to the questionnaire self-declared a diagnosis of JHS and 
this was not confirmed clinically. It should therefore be acknowledged that some 
respondents might have had other conditions. The questionnaire was not subjected 
to factor analysis to inform item reduction and questionnaire structure. The pragmatic 
design of the questionnaire, including the use of a range of different response 
options and adoption of the BRAF-NRS questions, complicated the effective use of 
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factor analysis for these purposes. In hindsight, a more standardised approach to 
response options might have facilitated further refinement of the questionnaire. The 
range of response options has also resulted in some items that attract a maximum 
score of 5 and others a maximum score of 10. The appropriateness of the relative 
weighting of questions is currently unknown, although the median total BIoH scores 
were almost identical when these items were scored out of 10 (median score 
234/360, 65.0%) as opposed to out of 5 (180.5/275, 65.6%). This is therefore 
unlikely to be a significant issue unless those items were to be affected differentially 
by an improvement or deterioration in the condition and this would need to be 
determined in future research. On a positive note, a very inclusive development 
process was employed which worked well. Initial validation has also been conducted 
on a very large sample size (n=615), although it should be noted that the sample 
lacked diversity with regards ethnicity, gender and educational attainment. 
 
Conclusion and future directions 
The new BIoH questionnaire has demonstrated initial potential to inform future 
research and clinical practice in this under-recognised and poorly managed 
condition. Future research needs to be conducted to determine other psychometric 
properties such as test-retest reliability, sensitivity to change, the minimum clinically 
important difference, and other aspects of validity, including Rasch analysis.   
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FIGURE CAPTION 
 
Figure 1. The total number of painful areas reported by individuals (n=614 valid 
responses). Participants were asked “During the past 7 days, have you had pain in 
any of the following areas?” and were given response options of ‘yes’ or ‘no’ to 10 
areas.  
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Characteristic  
(number of valid responses) 
Response  
(number of responses) 
% of valid responses 
Sex (614) Women (582) 94.8 
Men (32) 5.2 
Ethnicity (614) White (602) 98.0 
Mixed (5) 0.8 
Asian (2) 0.3 
Black (1) 0.2 
Chinese (1) 0.2 
Other (3) 0.5 
Relationship status (612) Single (177) 28.9 
Married/partner (378) 61.8 
Divorced/separated (48) 7.8 
Widowed (7) 1.1 
Other (2) 0.3 
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Living arrangements (595) Alone (96) 16.1 
With husband/ wife/ partner (356) 59.8 
With somebody else (143) 24.0 
Education* College diploma or equivalent (302/482) 62.7 
University degree or equivalent (292/519) 56.3 
Postgraduate degree (e.g. PhD) (76/392) 19.4 
Currently in paid employment 
(600) 
Yes (339) 56.5 
No (261) 43.5 
Hours of paid employment (324) Part-time (160) 49.4 
Full-time (159) 49.1 
Not applicable (5) 1.5 
Employment status (302) Self-employed (49) 16.2 
Employee (248) 82.1 
Self-employed and employee (1) 0.3 
Not applicable (4) 1.3 
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Table 1. Characteristics of responders to Stage 3. * More than one response could be selected so total n not reported and total 
% may be more than 100%. 
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“During the past 7 days, have you had pain in any of 
the following areas?” (number of valid responses) 
Number responding ‘Yes’ 
(% of valid responses) 
Back (613) 550 (89.7) 
Knees (611) 524 (85.8) 
Shoulders (611) 513 (84.0) 
Hips (610) 506 (83.0) 
Neck (601) 480 (79.9) 
Hands (605) 477 (78.8) 
Wrists (604) 470 (77.8) 
Feet (606) 439 (72.4) 
Ankles (603) 400 (66.3) 
Elbows (596) 292 (49.0) 
Table 2. Site of pain. Results are presented in order of frequency. 
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Question Reason for removal 
Median score  
≤40% 
Correlation  
≥0.7 
C. Please tick the box which best describes how much, during the past 7 days, hypermobility has affected… 
the clothing you have worn   
D. How often… 
have your hands seized up during the past 7 days?   
have you had difficulty getting comfortable in bed during the past 7 days?   
have you had trouble sleeping due to hypermobility during the past 7 days?   
has hypermobility kept you from your usual activities during the past 7 days?   
have you had difficulty walking a distance that would usually be OK for you during the 
past 7 days? 
  
has it been difficult to do your usual work activities (including unpaid work such as 
housework) during the past 7 days? 
  
has it been difficult to do your usual hobbies during the past 7 days?   
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E. How much difficulty have you had with the following tasks during the past 7 days due to hypermobility? 
Holding a mug or cup   
Doing up buttons   
Picking up a coin   
Washing dishes   
Using a door handle or lever   
Putting on socks   
Getting out of a car   
Making sharp turns while walking or running   
Pushing a shopping trolley or pushchair   
Getting dressed   
Raising your hands above your head repeatedly, e.g. to straighten hair or change a light 
bulb 
  
Turning over in bed   
Brushing or combing hair   
Pulling a light switch cord   
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Holding a frying pan   
Using a computer mouse or keyboard   
Getting out of bed without assistance   
F. How much discomfort would you have had after the following activities during the past 7 days? 
Climbing one flight of stairs   
Going down one flight of stairs   
Going up or down a flight of stairs without a handrail   
Walking at your own pace for 5 minutes   
Walking briskly for 5 minutes   
G. Please circle the number which best indicates… 
how able you have felt to cope with pain during the past 7 days   
thinking about what you are usually able to do, how much you have felt in control of 
your ability to do your usual activities during the past 7 days 
  
how much pain has interfered with your ability to take part in social or family activities 
during the past 7 days 
  
H. Please tick the box which best indicates your agreement with the following statements. 
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I am concerned about tripping or falling over when I am out and about   
I feel unsteady on my feet   
I feel anxious about falling or tripping   
I can control the position of my limbs   
I am able to cope with my pain    
I am able to manage my pain   
Supplemental information 1. Details of the removed questionnaire items and reasons for their exclusion.  = Met this 
criterion and used to inform removal of this item.  = Did not meet this criterion.
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SF36 Domains Median (IQR) Spearman’s Rank 
Correlation Coefficient (r) 
Physical Component Score (PCS) 31.9 (14.5) -0.725* 
 Physical Functioning (PF) 40.0 (45.0) -0.779* 
Role Physical (RP) 34.4 (43.8) -0.756* 
Bodily Pain (BP) 31.0 (29.0) -0.787* 
General Health (GH) 27.0 (30.0) -0.567* 
Mental Component Score (MCS) 44.1 (17.6) -0.447* 
 Vitality (VT) 25.0 (25.0) -0.624* 
Social Functioning (SF) 50.0 (50.0) -0.717* 
Role Emotional (RE) 75.0 (50.0) -0.476* 
Mental Health (MH) 65.0 (30.0) -0.455* 
Table 3. Median SF-36 component scores and correlation against the total 
BIoH score. * All p<0.001. 
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Figure 1.  
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Supplemental information 2. The Bristol Impact of Hypermobility (BIoH) 
questionnaire. 
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Supplemental information 3. The Bristol Impact of Hypermobility (BIoH) 
questionnaire scoring guidance. 
 
